MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. by Xu, Shaohua et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Pathology, Anatomy and Cell
Biology Faculty Papers
Department of Pathology, Anatomy and Cell
Biology
9-22-2015
MiR-497 decreases cisplatin resistance in ovarian
cancer cells by targeting mTOR/P70S6K1.
Shaohua Xu
Department of Obstetrics and Gynecology, Shanghai First Matenity and Infant Hospital, Tongji University School of Medicine
Guang-Bo Fu
Department of Urology and Pathology, Huai'an First People's Hospital, Nanjing Medical University
Zhen Tao
Department of Science and Technology, Radiation Oncology Department, Tianjin Medical University Cancer Hospital and
Institute
Jun OuYang
Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University
Fanfei Kong
Department of Obstetrics and Gynecology, Shanghai First Matenity and Infant Hospital, Tongji University School of Medicine
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/pacbfp
Part of the Medical Cell Biology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Pathology, Anatomy and Cell Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Xu, Shaohua; Fu, Guang-Bo; Tao, Zhen; OuYang, Jun; Kong, Fanfei; Jiang, Bing-Hua; Wan,
Xiaoping; and Chen, Ke, "MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting




Shaohua Xu, Guang-Bo Fu, Zhen Tao, Jun OuYang, Fanfei Kong, Bing-Hua Jiang, Xiaoping Wan, and Ke
Chen
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/pacbfp/173
Oncotarget26457www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 28
MiR-497 decreases cisplatin resistance in ovarian cancer cells 
by targeting mTOR/P70S6K1
Shaohua Xu1,*, Guang-Bo Fu2,*, Zhen Tao4, Jun OuYang5, Fanfei Kong1, Bing-Hua 
Jiang6,7, Xiaoping Wan1 and Ke Chen3
1 Department of Obstetrics and Gynecology, Shanghai First Matenity and Infant Hospital, Tongji University School of Medicine, 
Shanghai, China
2 Department of Urology and Pathology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
3 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Department of Science and Technology, Radiation Oncology Department, Tianjin Medical University Cancer Hospital and 
Institute, Tianjin, China
5 Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Changzhou, China
6 State Key lab of Reproductive Medicine, Cancer Center, Nanjing Medical University, China
7 Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA
* These authors have contributed equally to this work
Correspondence to: Xiaoping Wan, email: wanxiaoping61@126.com
Correspondence to: Ke Chen, email: shenke@tjh.tjmu.edu.cn
Keywords: miR-497, mTOR, p70S6K1, cisplatin resistance, ovarian cancer
Received: January 13, 2015 Accepted: June 25, 2015 Published: July 03, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
The mechanism of cisplatin resistance in ovarian cancer is not clearly understood. 
In the present investigation, we found that the expression levels of miR-497 were 
reduced in chemotherapy-resistant ovarian cancer cells and tumor tissues due 
to hypermethylation of miR-497 promoter. Low miR-497 expression levels were 
associated with chemo-resistant phonotype of ovarian cancer. By analyzing the 
expression levels of miR-497, mTOR and p70S6K1 in a clinical gene-expression array 
dataset, we found that mTOR and p70S6K1, two proteins correlated to chemotherapy-
resistance in multiple types of human cancers, were inversely correlated with miR-
497 levels in ovarian cancer tissues. By using an orthotopic ovarian tumor model 
and a Tet-On inducible miR-497 expression system, our results demonstrated 
that overexpression of miR-497 sensitizes the resistant ovarian tumor to cisplatin 
treatment. Therefore, we suggest that miR-497 might be used as a therapeutic 
supplement to increase ovarian cancer treatment response to cisplatin.
INTRODUCTION
Epithelial ovarian carcinoma is the leading cause 
of death worldwide from gynecological malignancies [1]. 
Despite current multidisciplinary treatment, the overall 
prognosis remains disappointing [2, 3]. More than 75% 
of patients diagnosed with epithelial ovarian carcinoma 
are at advanced-staged, and the 5-year survival rate is 
less than 30% [4]. Cisplatin is one of the most effective 
and commonly used chemotherapeutics agents for the 
treatment of ovarian cancer. However, the development 
of cisplatin-based resistance limits its successful clinical 
application in cancer patients [5]. Despite the knowledge 
that has been accumulated over decades, the mechanisms 
of cisplatin resistance are not fully understood. 
 MiRNAs are small endogenous non-coding 
RNAs composed of about 19-24 nucleotides that bind 
to imperfect sequence homology sites of mRNA and 
recruit the RNA-induced silencing complex, causing 
either degradation or inhibition of protein translation, thus 
effectively silencing their mRNA targets [6]. It has been 
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reported that miRNA-mediated gene regulation involvoed 
in biological processes including cell proliferation, 
migration and invasion, differentiation, survival, and 
tumorigenesis [7, 8]. Recent studies showed that miRNAs 
also play a vital role in chemotherapeutic resistance [9, 
10], highlighting miRNAs as potent therapeutic targets 
or chemoresistant modulators in cancer treatment. MiR-
497 is one of the tumor suppressor miRNAs in human 
cancer. Downregulation of miR-497 has been found in 
breast, cervical, head-and-neck, colorectal, and prostate 
cancer [11-14]. Reduced expression of miR-497 has been 
associated with malignancy of breast and colorectal cancer 
[11, 14]. In addition, forced expression of miR-497 is able 
to suppress cancer cell growth both in vitro and in vivo 
[15-16]. Finally, increasing evidence indicates that miR-
497 negatively regulates numerous well-characterized 
oncogenic proteins, such as IGF-1R [13], CCND1 [11], 
CDC25A, CDK6, CDK4 [17], and BCL-2 [18]. Although 
miR-497 has been shown to be a tumor suppressor gene 
in many human cancers, its role in chemotherapeutical 
resistance has not been fully addressed. The objective 
of this study was to reveal the molecular mechanisms of 
miR-497 in cisplatin-resistant ovarian cancer. 
RESULTS
MiR-497 expression was downregulated in 
cisplatin-resistant ovarian cancer cell lines and 
ovarian cancer specimens
To determine the crucial miRNAs involved in 
ovarian cancer cisplatin resistance, we performed 
microarray assay to profile the global expression of mature 
miRNAs in A2780 and A2780/CP cell lines. The signal 
ratios of A2780/CP to A2780 were assessed. Differentially 
expressed miRNAs with at least 2-fold alternation were 
selected (Figure 1A). Consistent with other studies, we 
also found that let-7e and let-7i were among the top 10 
Figure 1: The expression levels of miR-497 were downregulated in cisplatin-resistant ovarian cancer cells. A. miRNA 
array analysis showed that miRNAs were differentially expressed in A2780 and A2780/CP cells. The pseudocolar represents the intensity 
scale of A2780 versus A2780/CP cells. B.-E. Relative expression levels of Let-7e, Let-7i, miR-214, and miR-497 in A2780 and A2780/CP 
cells were determined by Taqman qRT-PCR assay, and normalized to the U6 levels. F. Relative expression levels of miR-497 in SKOV3 
and SKOV3/CP cells were determined by Taqman qRT-PCR assay, and normalized to the U6 levels. G. Relative expression levels of miR-
497 in 20 different platinum-sensitive and 21 different platinum-resistant ovarian tumors. All results represent the mean ± SD from three 
independent experiments. 
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downregulated miRNAs and miR-214 was upregulated in 
A2780/CP compared with A2780. Importantly, miR-497 
was remarkably downregulated in A2780/CP compared 
with A2780 (Figure 1B-1E). To further validate this 
finding, we examined miR-497 expression levels in 
SKOV3 and SKOV3/CP cell lines. The results showed 
that miR-497 levels were significantly reduced in SKOV3/
CP cells compared with SKOV3 cells (Figure 1F). We 
further investigated the association of miR-497 levels 
in primary ovarian tumors and its response to platinum-
Figure 2: The expression of miR-497 was regulated by DNA methylation. A. MSP analyses of miR-497 gene promoter in 
A2780, A2780/CP, SKOV3 and SKOV3/CP cells. U indicated unmethylated status; M indicated methylated status. B. A2780/CP and 
SKOV3/CP cells were treated with 5-Aza-dC for 5 days. The methylation of miR-497 promoter in the cells was analyzed using MSP. C.-
D. A2780/CP and SKOV3/CP cells were treated without or with 5-Aza-dC for 5 days. Pri-miR-497 and miR-497 expression levels were 
measured by qRT-PCR. The graphs show the mean ± SD of the relative levels from three replications. E.-F. MSP analyses of miR-497 gene 
promoter in 14 different pairs of platinum-sensitive and platinum-resistant ovarian tumors.
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based chemotherapy. We found that miR-497 levels were 
significant lower in platinum sensitive tumors compared 
with platinum resistant tumors (Figure 1G), indicating that 
miR-497 may play an important role in the development of 
cisplatin resistance in ovarian cancer. 
MiR-497 downregulation was due to DNA 
methylation
To explore the mechanism of miR-497 
downregulation in cisplatin-resistant ovarian cancer cells, 
we first analyzed the genomic DNA sequence within 
3-kilobase promoter regions of miR-497 gene, and found 
miR-497 gene contains CpG-rich regions (CpG islands) 
in its promoter regions. We compared methylation 
status of the promoter of miR-497 in A2780 and A2780/
CP or in SKOV3 and SKOV3/CP cells by methylation-
specific PCR (MSP) analysis. Hypermethylation of 
miR-497 promoter was identified in A2780 and SKOV3 
cells compared with A2780/CP and SKOV3/CP cells, 
respectively (Figure 2A-2B). To further determine 
whether DNA methylation is responsible for miR-497 
downregulation, we treated A2780/CP and SKOV3/CP 
cells with or without 5-Aza-dC, a demethylation reagent, 
and performed MSP assay. Demethylation treatment 
by 5-Aza-dC dramatically restored both pri-miR-497 
and matured miR-497 expression levels in A2780/CP 
and SKOV3/CP cells (Figure 2C-2D), indicating that 
hypermethylation plays a crucial role in the silencing of 
Figure 3: Overexpression of miR-497 reduces resistance of ovarian cancer cells to cisplatin treatment. A.-B. A2780/CP 
and SKOV3/CP cells were transfected with pre-miR-497, or scrambled miRNA precursors A. or with anti-miR-497, or scrambled miRNA 
inhibitors B.. Cells were treated with cisplatin for 72 h. The cell viability rate was analyzed by MTT assay. C.-D. Serum starved A2780/CP 
and SKOV3/CP cells with stable overexpression of miR-497, then exposed to various concentrations of cisplatin for 48 h. IC50 values were 
determined. E. A2780/CP and SKOV3/CP cells were transfected with pCMV-Tet3G, and selected by G418 for stably transfected cells. Then 
cells were transfected with pTRE3G-miR-497 or pTRE3G-miR-NS and were selected by puromycin. Cells were exposed to Doxycycline 
(Dox) (500 ng/ml) for 48 h, and total RNAs were extracted. The expression levels of miR-497 were analyzed by Taqman qRT-PCR assay. F. 
Cells as indicated were exposed to Dox (500 ng/ml) for 48 h before treated with cisplatin for 72 h. MTT assay was used to test cell viability 
after cisplatin treatment. All results represent the mean ± SD from three independent experiments. 
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miR-497 expression. We next analyzed miR-497 promoter 
methylation status in 28 ovarian cancer samples. The 
MSP results showed that the methylation levels of miR-
497 promoter regions in platinum resistant tumors were 
dramatically higher than those in platinum sensitive 
tumors (Figure 2E-2F). Collectively, these results 
indicated that DNA hypermethylation may be the main 
reason for miR-497 downregulation in ovarian cancer 
cells. 
MiR-497 is involved in cisplatin-resistant ovarian 
cancer phonotype
To investigate the roles of miR-497 in cisplatin-
resistant phonotype of ovarian cancer cells, we forced 
expression of miR-497 in A2780/CP and SKOV3/CP cells 
with low endogenous miR-497 levels by transfection of 
cells with miR-497 precursor or a control precursor (miR-
NS). We also inhibited levels of miR-497 in A2780 and 
SKOV3 cells by transfection of cells with anti-miR-497 
inhibitor or a control inhibitor (anti-miR-NS). MiR-497 
overexpression dramatically reduced A2780/CP and 
SKOV3/CP cells resistance to cisplatin (Figure 3A). On 
the contrary, inhibition of miR-497 expression markedly 
increased A2780 and SKOV3 cells tolerance to cisplatin 
(Figure 3B). Furthermore, consistent with the results from 
MTT assay, we found that overexpression of miR-497 
significantly sensitized A2780/CP and SKOV3/CP cells to 
cisplatin treatment (Figure 3C-3D). Next, we generated 
Tet-On-based stable cell lines for inducible expression 
of miR-497 in A2780/CP-Tet-ON-miR-497 and SKOV3/
CP-Tet-ON-miR-497 cells. Doxycycline (Dox) treatment 
significantly increased miR-497 expression in A2780/CP-
Tet-ON-miR-497 and SKOV3/CP-Tet-ON-miR-497 cells, 
as compared with miR-NS expressing cells or doxycycline 
non-treatment groups (Figure 3E). We observed that miR-
497 over-expression in A2780/CP and SKOV3/CP cells 
resulted in much stronger cisplatin treatment response 
than transient miR-497 restoration. Dox treatment altered 
miR-497 expression or cisplatin resistance of both A2780/
CP and SKOV3/CP cells (Figure 3F). Taken together, 
downregulation of miR-497 expression render ovarian 
cancer cells resistant to cisplatin treatment.
mTOR and p70S6K1 are direct targets of miR-
497
To investigate the molecular mechanisms of how 
miR-497 decreases cisplatin resistance, we employed 
several well-developed miRNA algorithms, such as 
TargetScan, PicTar, and miRNA.org, to obtain a list of 
possible mRNA targets of miR-497. Among the search 
results, mTOR and p70S6K1 captured our attention 
because they were reported to be involved in cisplatin 
resistance in multiple human cancers [19-21] (Figure 4A). 
To confirm these targets, reporter constructs were made to 
contain the putative binding sites of mTOR and p70S6K1 
3’-UTR regions, or with 3 nucleotide substitute in their 
3’-UTR regions (Mut). The luciferase activities from the 
mTOR and p70S6K1 wild-type construct were inhibited 
upon overexpression of miR-497 and were induced by 
inhibition of miR-497. Point mutations in putative binding 
site abrogated the effect of miR-497, demonstrating that 
miR-497 specifically target the mTOR and p70S6K1 3’ 
UTR by binding to the identified seed sequence (Figure 
4B-4C). Furthermore, forced expression of miR-497 by 
transient transfection repressed both mTOR and p70S6K1 
protein expression in A2780/CP and SKOV3/CP cells; 
whereas blockade of endogenous miR-497 using antisense 
inhibitors increased both mTOR and p70S6K1 expression 
levels in A2780 and SKOV3 (Figure 4D-4E). Similar 
effects of miR-497 on targeting mTOR and p70S6K1 
have also been observed in multiple human cancer 
cells (data not shown). No significant differences were 
found in mTOR and p70S6K1 mRNA levels (data not 
shown), indicating that mTOR and p70S6K1 expression 
is regulated at the translational level through miR-497. 
These results demonstrated that miR-497 directly targets 
mTOR and p70S6K1 to repress their protein expression by 
binding to their 3’-UTR regions. 
MiR-497 decreases cisplatin resistance through 
targeting mTOR and p70S6K1
We found that the expression levels of mTOR and 
p70S6K1 were upregulated in cisplatin-resistant ovarian 
cancer cells (A2780/CP and SKOV3/CP) compared with 
cisplatin-sensitive cells (A2780 and SKOV3) (Figure 
5A). To investigate whether miR-497 overexpression 
enhanced the cisplatin response sensitivity of ovarian 
cancer cells via targeting mTOR and p70S6K1, we 
performed mTOR and p70S6K1 loss- and gain-of-
function experiments in ovarian cancer cells. Doxycycline 
treatment-induced stable-expressing miR-497 constantly 
decreased both mTOR and p70S6K1 expression in A2780/
CP and SKOV3/CP, as well as dramatically reduced 
cells resistance to cisplatin treatment (Figure 5B-5C). 
Knockdown of endogenous mTOR and p70S6K1 exerted a 
similar effect as overexpression of miR-497 on decreasing 
resistance of ovarian cancer cells (Figure 5D). Next, we 
used lentiviral particles carrying mTOR or p70S6K1 
cDNAs lacking their 3’-UTR regions to infect miR-497 
stable-expressing ovarian cancer cells. Interestingly, 
forced expression of mTOR and p70S6K1 partially 
or completely restored miR-497-inhibited cisplatin 
resistance in ovarian cancer cells (Figure 5E-5F). These 
results indicated that miR-497 downregulation promotes 
acquisition of cisplatin-resistant ability in ovarian cancer 
cell via inducing mTOR and p70S6K1 overexpression.
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Figure 4: mTOR and p70S6K1 are two direct targets of miR-497. A. The figure shows the alignment of miR-497 putative 
binding sites in human mTOR and p70S6K1 3’-UTR regions. B.-C. The reporter constructs containing the wild-type and mutant (Mut) 
p70S6K1 B. or mTOR C. 3’ -UTR regions were co-transfected into A2780/CP cells with miR-497, or scramble miRNA precursors; or 
anti-miR-497, or anti-scramble miRNA inhibitors and β-gal plasmid. The relative luciferase/β-gal activities were analyzed in the cells 48 
h after the transfection. All experiments were performed in triplicate. Bars indicate relative luciferase activities ± SD. * indicated p < 0.05. 
D. A2780/CP and SKOV3/CP cells were transfected with miR-497 or miR-Scr; or E. A2780 and SKOV3 cells were transfected with anti-
miR-497 or anti-miR-Scr inhibitors for 72 h. The expression levels of mTOR or p70S6K1 were analyzed by Western blotting. Relative 
expression levels of mTOR or p70S6K1 in 21 different platinum-sensitive and 20 different platinum-resistant ovarian tumors. 
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Figure 5: MiR-497 inhibits cisplatin resistance through targeting mTOR and p70S6K1 in ovarian cancer cells. A.-B. 
The expression levels of mTOR and p70S6K1 in A2780, A2780/CP, SKOV3 and SKOV3/CP cells A.; or in A2780/CP-Tet-ON-miR-497 
or SKOV3/CP-Tet-ON-miR-497 cells exposed to Dox for 48 h B., were measured by Western blotting. C. A2780/CP-Tet-ON-miR-497 or 
SKOV3/CP-Tet-ON-miR-497 cells were exposed to Dox for 48 h and treated with cisplatin for 72 h. The cells viability rate was analyzed 
by MTT assay. D. A2780/CP and SKOV3/CP cells were transfected with si-mTOR or si-p70S6K1, or scrambled control. Cells were treated 
with cisplatin for 72 h. The cells viability rate was analyzed by MTT assay. E.-H. A2780/CP-Tet-ON-miR-497 or SKOV3/CP-Tet-ON-
miR-497 cells were maintained in the medium with or without Dox and were infected using lentivirus carrying Scr, mTOR or p70S6K1 for 
48 h. Then the cells were treated with cisplatin for 72 h before MTT assay. 
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MiR-497 attenuates cisplatin resistance in 
orthotopic ovarian animal model
To test whether restoration of miR-497 expression 
in cisplatin-resistant ovarian cancer cells can enhance the 
response of cisplatin treatment in vivo, we established an 
orthotopic ovarian tumor model by implantation of A2780/
CP-Tet-ON-miR-497 or A2780/CP-Tet-ON-miR-NS cells 
in nude mouse ovary. On Day 6 after cell implantation, 
tumor-bearing mice were given drinking water with Dox 
every day to induce miR-497 or miR-NS expression. On 
Day 4, the mice received tail vein injection of cisplatin 
every five days for a total of 30 days. After 34 days of cell 
implantation, the mice were euthanized and tumors were 
collected (Figure 6A). As shown in Figure 6B-6D, tumor 
weights and volume in the miR-497 + cisplatin group 
were smaller than those in the miR-NS + cisplatin group. 
The levels of miR-497 were significantly higher and the 
levels of mTOR and p70S6K1 were dramatically lower 
in A2780/CP-Tet-ON-miR-497 formed tumors than those 
in A2780/CP-Tet-ON-miR-NS formed tumors (Figure 6E-
6F). 
Figure 6: MiR-497 overexpression decreased cisplatin resistance of ovarian cancer cells in vivo. A. Schematic of animal 
experimental procedure. B. Tumor weight from two groups was obtained and presented. C. Tumor size was measured every 5 days and 
tumor growth curves were showed. D. The expression levels of miR-497 in tumor tissues were analyzed by qRT-PCR. E. The representative 
image of the protein levels of mTOR and p70S6K1 were analyzed by western blotting.
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MiR-497 levels were inversely correlated with 
mTOR and p70S6K1 levels in tissues from 
ovarian cancer patients
The above studies showed that miR-497 directly 
target mTOR and p70S6K1 to repress their protein 
expression by binding to their 3’-UTR regions. To further 
test the physiological relevance of mTOR/p70S6K1 and 
miR-497 interaction, we performed in silico analysis 
for miR-497 and mTOR/p70S6K1 expression from The 
Cancer Genome Atlas (TCGA) 2011 dataset for Ovarian 
Cancer, comprising of 489 patient samples with follow-
up information (Figure 7A). As shown in Figure 7B-7D, 
miR-497 and mTOR/p70S6K1 were inversely correlated 
in ovarian cancer tissues, while mTOR and p70S6K1 were 
positively correlated.
Figure 7: Reduced expression of miR-497 was inversely correlated to mTOR/p70S6K1 levels of ovarian cancer patients. 
A. Heatmap depicting data from TCGA 2011 ovarian cancer microarray datasets that were assigned to ovarian cancer gene expression 
subtypes (n = 489). B. miR-497 levels were inversely correlated to mTOR expression levels in human ovarian cancer (R = -0.1811, P < 
0.0001). C. miR-497 levels were inversely correlated to p70S6K1 levels in human ovarian cancer (R = -0.09128, P = 0.043). D. mTOR 
expression levels were positively correlated to p70S6K1 levels in human ovarian cancer (R = -0.2841, P < 0.0001). E.-F. Real-time PCR 
was also performed to determine mTOR and p70S6K1 expression in 20 different platinum-sensitive and 21 different platinum-resistant 
ovarian tumors. Both mTOR and p70S6K1 levels were significantly upregulated in platinum resistant tumors compared with platinum 
sensitivity tumors. G.-H. Spearman’s rank correlation analysis revealed an inverse correlation between miR-497 and mTOR levels (R = 
-0.526, P = 0.001), and p70S6K1(R = -0.594, P = 0.001) exists in our ovarian cancer tumor samples.
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 Next, mTOR and p70S6K1 mRNA levels were 
quantified using real-time PCR. We observed that both 
mTOR and p70S6K1 were significantly upregulated 
in platinum resistant tumors compared with platinum 
sensitivity tumors, respectively (Figure 7E-7F). 
Furthermore, spearman’s rank correlation analysis 
revealed an inverse correlation between miR-497 and 
mTOR, and p70S6K1 exists in our ovarian cancer samples 
(Figure 7G-7H). Taken together, these results showed 
lower expression levels of miR-497 were inversely 
correlated with mTOR/p70S6K1 levels of ovarian cancer 
patients.
DISCUSSION
Previous studies have reported that miRNAs are 
aberrantly expressed in ovarian cancer and are associated 
with tumor stages, histological subtypes, recurrent tumors 
and survival [22-26]. Recently, increasing evidence also 
showed that miRNAs can affect sensitivity of ovarian 
cancer to various chemotherapy agents. For example, 
low levels of let-7i associated with chemoresistance 
in ovarian cancer and knockdown of let-7i decreased 
cisplatin-induced ovarian cancer cell death [10]. MiR-
200c overexpression may increase the sensitivity to 
microtubule-targeting drugs through repressing the 
expression of the tubulin molecule TUBB3 [27]. In 
addition, miR-214 is involved in chemosensitivity 
by modulating PTEN expression, an important tumor 
suppressor gene [9]. Thus far, only a limited number of 
miRNAs has been found to impact chemoresistance in 
ovarian cancer and the effect of miRNAs in mediating 
sensitivity to anticancer treatment in ovarian cancer 
remain incompletely understood. In the present study, 
we performed miRNA expression profiling in cisplatin-
sensitive cell lines (A2780) and cisplatin-resistant cell 
lines (A2780/CP). Our results showed that downregulation 
of let-7i, let-7e and upregulation of miR-214 in A2780/CP 
compared with A2780. Based on our previously studies 
[28, 29], we identified miR-497 as a new miRNA involved 
in cisplatin sensitivity. The expression levels of miR-497 
were significantly decreased in both cisplatin-resistant cell 
lines (A2780/CP and SKOV3/CP) as well as in platinum-
resistant ovarian cancer tissues. Overexpression of miR-
497 by transient transfection or Tet-ON-induced system 
decreased cisplatin-resistance of A2780/CP and SKOV3/
CP cells.
 Epigenetic modification such as DNA methylation 
has been shown to play an important role in the 
development of cisplatin resistance. Demethylation drug 
treatments have been shown to reverse cisplatin resistance 
by restoring the expression of certain resistance-related 
gene expression [30, 31]. However, there is less evidence 
showing that epigenetic regulated miRNAs contribute 
to the development of a cisplatin-resistant phenotype. 
Our results demonstrated that increased methylation of 
the miR-497 promoter play a crucial role for silencing 
expression of miR-497 and demethylation by 5-AZA 
treatment can reverse miR-497 expression in cisplatin-
resistant ovarian cancer cells. The molecular mechanism 
of cisplatin-induced hyper-methylation of miR-497 gene 
will be the focus of our future study.
 Our results demonstrated that mTOR and p70S6K1 
are two direct targets of miR-497, highlighting the 
potential role of miR-497 downregulation for ovarian 
cancer cells to develop a chemoresistance phenotype. The 
mTOR/p70S6K1 signaling pathway has been reported as a 
critical regulator of cellular metabolism, growth, survival, 
and drug resistance [32-34]. Overexpression of mTOR 
or p70S6K1 has been found in many human cancers and 
is associated with tumor malignancy and poor prognosis 
[35, 36]. However, the mechanisms of posttranscriptional 
regulation of mTOR or p70S6K1 have yet to be elucidated. 
We showed that miR-497 could suppress both mTOR 
and p70S6K1 protein expressions through the binding of 
these miRNAs to their 3’-UTR regions. Downregulation 
of miR-497 contributes to high levels of mTOR and 
p70S6K1, which makes ovarian cancer cells resistant to 
cisplatin-based chemotherapy. 
To study the impact of miR-497 in ovarian cancer 
tumor resistance to cisplatin treatment in vivo, we 
employed an orthotopic ovarian tumor model and a Tet-
On inducible miR-497 system. In the orthotopic ovarian 
tumor model, ovarian tumors were formed in mice 
normal ovary, which provides a better microenvironment 
than subcutaneous injection. The advantage of the Tet-
On inducible miR-497 system is that the expression of 
miR-497 is more controllable by addition or depletion 
of Dox in drinking water than long-term continuous 
stable-expressing miR-497 cell lines. Our data showed 
that induced-expressing of miR-497 in cisplatin-resistant 
ovarian cancer cells exert a much better cisplatin 
treatment effect on ovarian tumor growth than control 
groups, indicating a possible application for miR-497 
as a “supplement” to conventional cisplatin-based 
chemotherapy. Applied cisplatin with miR-497 may help 
to reduce the rate of cisplatin-resistant ovarian cancer 
occurrence and improve the overall response rate to 
chemotherapy. 
 In conclusion, our study demonstrated that 1) miR-
497 was downregulated in cisplatin-resistant ovarian 
cancer cell lines and tumors; 2) DNA hypermethylation 
contribute to downregulation of miR-497; 3) mTOR and 
p70S6K1 are two direct targets of miR-497 with biological 
function that are associated with development of cisplatin-
resistance phonotype; and 4) overexpression of miR-497 
decreases cisplatin resistance of ovarian cancer cells in 
vitro and in vivo. 
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MATERIALS AND METHODS
Cell lines and reagents
The human ovarian cancer cell lines A2780, A2780/
CP, SKOV3, and SKOV3/CP were purchased from The 
Cell Bank of Chinese Academy of Science. Cells were 
maintained in a medium of RPMI 1640 supplemented 10 
% FBS and 1 % penicillin/streptomycin and were kept in 
5 % CO2 incubator at 37°C. Antibodies against mTOR, 
p70S6K1 and β-actin were purchased from Cell Signaling 
Technology. siRNAs targeting mTOR or p70S6K1 were 
purchased from Thermo Scientific as specific oligo pools. 
For demethylation treatment, cells were treated with 5 
µM of 5-Aza-2’-deoxycytidine (5-Aza-dC) (Sigma, MO, 
USA) for 120 h, with replacing the fresh drug each day. 
Cisplatin was obtained from Sigma (St. Louise, MO). 
Tissue samples
A collection of 41 different kinds of fresh-frozen 
ovarian cancer tumor specimens were from the tissue bank 
of Nanjing Medical University. All tumor samples were 
collected immediately after the surgical removal and snap-
frozen in liquid nitrogen. The clinical characteristics of the 
ovarian cancer patients are listed in Table 1. All patients 
provided written informed consent and the experimental 
procedures were approved by the Institutional Review 
Board of the Nanjing Medical University. Progression-free 
survival (PFS) was calculated from time of surgery to time 
of progression or recurrence. PFS > 6 months was defined 
as sensitivity to the last platinum-based chemotherapy; 
and PFS < 6 months was defined as resistant to the last 
platinum-based chemotherapy.
Construction of Tet-On 3G inducible expression 
systems
Tet-On 3G inducible expression systems were 
purchased from Clontech Laboratories, Inc. The hsa-
miR-497 and hsa-miR-NS fragments were PCR amplified 
from hsa-miR-497 and hsa-miR-NS overexpression 
plasmids obtained from Open biosystems. The purified 
fragments were inserted into pTRE3G plasmid to obtain 
pTRE3G-miR-497 or pTRE3G-miR-NS plasmid. pCMV-
Tet3G plasmid was transfected into target cells, then 
selected by G418 for stably expressing cells. Then cells 
were transfected with pTRE3G-miR-497 or pTRE3G-
miR-NS plasmid. After a second round of selection, cell 
lines were established and comfirmed for expressing high 
levels of hsa-miR-497 or hsa-miR-NS in response to 
doxycycline (Dox).
Transfection of cells with pre-miRNA precursors 
or anti-miRNA inhibitors
Hsa-miR-NS, hsa-miR-497 precursors, or anti-
miR-497 and control inhibitors (Ambion, TX, USA) were 
transfected into cells using Lipofectamine RNAiMAX 
(Invitrogen, CA, USA) according to the manufacturer’s 
instructions. Protein lysates and total RNAs were collected 
72 h after the transfection. The expression levels of 
miRNAs were verified by stem-loop qRT-PCR analysis.
Quantitative real-time PCR
Total RNAs were isolated using Trizol Reagent 
(Life Technologies, Carlsbad, CA, USA) according to 
the manufacturer’s instructions. cDNAs were synthesized 
with TaqMan Reverse Transcription Reagents (Life 
Technologies). The expression levels of miRNAs were 
analyzed using Taqman MicroRNA Assay Kits (Applied 
Biosystems, Foster City, CA) specific for hsa-Let-7e, hsa-
Let-7i, hsa-miR-214, hsa-miR-497 precursors, p70S6K1 
and mTOR mRNAs. The fold stimulation was determined 
using the comparative cycle threshold method (2−∆∆CT) 
[37]. All experiments were performed in triplicate. 
Western blotting analysis
Cells were lysed in RIPA buffer with protein 
inhibitors. Total proteins (20-40 µg) from each sample 
were electrophoresised on 8 % SDS-PAGE gel, and 
transferred to a nitrocellulose membrane. The membranes 
were blocked in 5% nonfat milk and probed with the 
primary antibodies as indicated overnight at 4°C. The 
membranes were washed and probed with the secondary 
antibody conjugated to horseradish peroxidase and the 
developed with enhanced chemiluminescence (Thermo 
Scientific).R
DNA methylation analysis
Genomic DNAs were purified using DNA Mini 
kit (Qiagen, MD, USA). Genomic DNAs were modified 
with sodium bisulfite using the EpiTect Kit (Qiagen) 
following the manufacturer’s instruction, then analyzed by 
methylation-specific PCR (MSP) using primers for either 
methylated or unmethylated DNA. 
Methylation-specific PCR primers are summarized 
as follows:
MiR-497 MF: 5’- 
TTGATTTAGGGAGAGGAAGGAC -3’
MiR-497 MR: 5’- 
TAAACAAACAACTAAAAAACGACGA -3’
MiR-497 UF: 5’- 
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TTTGATTTAGGGAGAGGAAGGAT -3’
MiR-497 UR: 5’- 
AAACAAACAACTAAAAAACAACAAA -3’
Luciferase reporter assay
mTOR and p70S6K1 3’-UTR regions containing 
predicted miR-497 binding sites and corresponding mutant 
sites were amplified by PCR from genomic DNA, and the 
PCR fragments were inserted into untranslated region 
Table 1: Clinical characteristics of ovarian cancer patients
Patient Characteristics (N = 41)
Characteristic PSF > 6 (N = 20) PSF < 6 (N = 21)
Age
                            < 50 4 4
                            > 50 16 17
Stage
                             I-II 5 3
                            III-IV 15 18
Grade
                             0 0 0
                             1 1 0
                             2 4 5
                             3 15 16
Histologic subtypes
                         Serous 14 19
                      Mucinous 3 1
                    Endometrioid 3 1
Debulking status
                   Optimal (≤1cm) 7 7
                Suboptimal (>1cm) 13 14
Chemotherapy response
                    Sensitive 20 0
                    Resistant 0 21
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(UTR) downstream of the luciferase gene in the pMIR-
reporter luciferase vector (Ambion). Luciferase reporter 
plasmid, β-galactosidase (β-gal) plasmid, and pre-miR-497 
and negative control precursors were cotransfected into 
cells using Lipofectamine 2000 (Invitrogen). Luciferase 
activities were measured 48 hours after transfection using 
β-gal for normalization. Primers used for Luciferase 
reporter constructs as follows:
mTOR Wild-type F: 5’- GCCGAGCTCTT 
TTCTGAGGCTTTTGTA-3’
mTOR Wild-type R: 5’- GCGAAGCTTCTAGGT 
CATTCTTCCATC-3’
mTOR Mutant F: 5’- GCCGAGCTCGGTTT 
GAACCAACTTTCTAGCTGCTGTTGAAGAATATATT 
GTCAGAAGCTTCGC - 3’
mTOR Mutant R: 5’- GCGAAGCTT 
CTGACAATATATTCTTCAACAGCAGCTAGAAAGTT 
GGTTCAAACCGAGCTCGGC-3’
p70S6K1 Wild-type F: 5’- GCCGAGCT 
CTAGCCCTTGAGCCCTGTCC-3’
p70S6K1 Wild-type R: 5’- GCGAAGCTTATT 
CAGCCCTTTAATCTTCCAC-3’
p70S6K1 Mutant F: 5’- GCCGAGCTC 
GGAGATAGGGATATCCAGGGGAAGAGGGTGTAGC 
TGTGGCCCACAAGCTTCGC-3’




Cells (1×104) were seeded into 96-well plates. 
After cellular adhesion, medium containing cisplatin at 
distinct concentrations (0.1-1000 μM) was added to the 
corresponding cells. After 72 h, cell viability was assessed 
using the MTT Cell Proliferation Assay (life technologies). 
MTT reagent was prepared in fresh medium (100 μL 
medium + 20 μL MTT solution) and applied to the cells. 
The absorbance at 590 nm for each well was read on a 
spectrophotometer [38].
Mouse xenograft models
BALB/c athymic nude mice were housed and 
maintained in a laminar airflow cabinet in a pathogen-
free environment. Mice were anaesthetized and ovarian 
were exposed. A2780/CP-Tet-On-miR-NS or A2780/
CP-Tet-On-miR-497 cells (1x106) were injected into 
the ovarian capsule via sterile microsyringe. The mice 
were feed drinking water with Dox to induce miR-497 
expression 6 days after the injection. On day 4 after tumor 
cells implantation, cisplatin intravenously (i.v) by tail 
vein injections every 5 days. The mice were sacrificed by 
euthanasia. The maximum tumor size was not exceed 1 
cm3. Primary tumors were harvested from mice, and the 
tumor volumes were determined according to the formula 
of 1/2 (length×width×height).
Coexpression analysis of 2011 TCGA dataset
A normalized mRNA expression dataset for ovarian 
cancer [39] was downloaded from the cBioPortal for 
cancer genomics and used to evaluate coexpression 
of mTOR, p70S6K1, and miR-497 transcript levels. 
This dataset includes mRNA profiles for 489 primary 
tumor samples. Spearman’s correlation coefficiency was 
calculated for these transcripts for all primary tumor 
samples. Differences were considered significant with p 
< 0.05. 
Statistical analysis
All results were analyzed using SPSS for windows 
version 13 (SPSS, Chicago, IL, USA). Quantitative 
variables were analyzed by t-test or ANOVA. The 
correlations were analyzed using Spearman’s rank test. 
Differences were considered significant with p less 
than 0.05. Data represent mean plus SD from at least 3 
replications, unless indicated specifically otherwise.
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